Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03647085 · ClinicalTrials.gov registry record
Data Collection Atrial Fibrillation Exploratory Study
A clinical trial, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- 27
- Enrollment target
NCT03647085: Clinical Trial study, sponsored by Boston Scientific Corporation.
NCT03647085 is a clinical trial that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03647085 was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- 27 participants
- Enrollment target
Study Summary
To characterize the impact of Atrial fibrillation (AFib) and Atrial Flutter (AFl) on signals measured using a wearable cardiac monitor prototype device. To evaluate the relationship of AFib/AFl symptom severity with various physiologic signals measured from the wearable cardiac monitor prototype device.
Primary Outcome
Characterize the impact of Atrial fibrillation (AFib) and Atrial Flutter (AFl) on signals measured using a wearable cardiac monitor prototype device.
Interventions
- DEVICE Wearable cardiac monitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2018-08-29 |
| Est. Completion | 2019-01-10 |
Why NCT03647085 stopped before completion
NCT03647085 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 27 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Wearable cardiac monitor is the first listed.
NCT03647085 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03647085 about?
NCT03647085 is a clinical study titled "Data Collection Atrial Fibrillation Exploratory Study". To characterize the impact of Atrial fibrillation (AFib) and Atrial Flutter (AFl) on signals measured using a wearable cardiac monitor prototype device. To evaluate the relationship of AFib/AFl symptom severity with various physiologic signals measured from the wearable cardiac monitor prototype de...
What is the current status of trial NCT03647085?
This trial is currently terminated. The enrollment target is 27 participants. The study started on 2018-08-29. Estimated completion is 2019-01-10.
What interventions are being tested in trial NCT03647085?
The interventions under investigation include: Wearable cardiac monitor (DEVICE).
Who is sponsoring clinical trial NCT03647085?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI